West Pharmaceutical Services (NYSE:WST – Get Free Report) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $6.55 to $6.75 for the period, compared to the consensus EPS estimate of $6.42. The company issued revenue guidance of $2.875 billion to $2.905 billion from $2.870 billion to $2.900, compared to the consensus revenue estimate of $2.87 billion. West Pharmaceutical Services also updated its FY 2024 guidance to 6.550-6.750 EPS.
West Pharmaceutical Services Price Performance
West Pharmaceutical Services stock traded down $22.73 during mid-day trading on Friday, reaching $307.92. The company had a trading volume of 1,486,236 shares, compared to its average volume of 563,827. The stock’s 50-day simple moving average is $300.36 and its 200-day simple moving average is $322.86. The company has a market capitalization of $22.34 billion, a P/E ratio of 44.52, a P/E/G ratio of 10.21 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68. West Pharmaceutical Services has a 1 year low of $265.00 and a 1 year high of $413.70.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical instruments supplier reported $1.85 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.34. The firm had revenue of $746.90 million during the quarter, compared to the consensus estimate of $709.62 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. West Pharmaceutical Services’s quarterly revenue was down .1% on a year-over-year basis. During the same period last year, the business posted $2.16 EPS. On average, equities analysts predict that West Pharmaceutical Services will post 6.42 EPS for the current year.
West Pharmaceutical Services Increases Dividend
Insiders Place Their Bets
In other news, VP Charles Witherspoon sold 1,029 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the transaction, the vice president now directly owns 1,478 shares of the company’s stock, valued at $443,400. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.53% of the stock is currently owned by company insiders.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading
- Five stocks we like better than West Pharmaceutical Services
- 3 Stocks to Consider Buying in October
- Texas Roadhouse Stock Steering for New Highs This Year
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Using the MarketBeat Stock Split Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.